Trials / Completed
CompletedNCT02230761
Phase 2 Study of XAF5 (XOPH5) Ointment for Reduction of Excess Eyelid Fat (Steatoblepharon)
A Phase 2, Randomized, Double-masked, Placebo-controlled Study of XOPH5 Ointment for Reduction of Lower Lid Steatoblepharon
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 90 (actual)
- Sponsor
- Topokine Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 40 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study will test whether XAF5 (XOPH5) ointment, applied once daily to the lower eyelids for 10 weeks, reduces the prominence of lower eyelid fat in adults with moderate to severe steatoblepharon (excess eyelid fat).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | XOPH5 Ointment | |
| DRUG | Placebo |
Timeline
- Start date
- 2014-09-01
- Primary completion
- 2014-12-01
- Completion
- 2014-12-01
- First posted
- 2014-09-03
- Last updated
- 2016-02-08
- Results posted
- 2016-02-08
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02230761. Inclusion in this directory is not an endorsement.